A review on development and application of plant-based bioflocculants and grafted bioflocculants

Flocculation is extensively employed for clarification through sedimentation. Application of eco-friendly plant-based bioflocculants in wastewater treatment has attracted significant attention lately with high removal capability in terms of solids, turbidity, color, and dye. However, moderate flocculating property and short shelf life restrict their development. To enhance the flocculating ability, natural polysaccharides derived from plants are chemically modified by inclusion of synthetic, nonbiodegradable monomers (e.g., acrylamide) onto their backbone to produce grafted bioflocculants. This review is aimed to provide an overview of the development and flocculating efficiencies of plant-based bioflocculants and grafted bioflocculants for the first time. Furthermore, the processing methods, flocculation mechanism, and the current challenges are discussed. All the reported studies about plant-derived bioflocculants are conducted under lab-scale conditions in wastewater treatment. Hence, the possibility to apply natural bioflocculants in food and beverage, mineral, paper and pulp, and oleo-chemical and biodiesel industries is discussed and evaluated

Realization and Properties of Biochemical-Computing Biocatalytic XOR Gate Based on Enzyme Inhibition by a Substrate

We consider a realization of the XOR logic gate in a process biocatalyzed by an enzyme (here horseradish peroxidase: HRP), the function of which can be inhibited by a substrate (hydrogen peroxide for HRP), when the latter is inputted at large enough concentrations. A model is developed for describing such systems in an approach suitable for evaluation of the analog noise amplification properties of the gate. The obtained data are fitted for gate quality evaluation within the developed model, and we discuss aspects of devising XOR gates for functioning in "biocomputing" systems utilizing biomolecules for information processing

Modulation of boradiazaindacene emission by cation-mediated oxidative PET

[GRAPHIC

Determination of nutritional and bioactive properties in some selected wild growing and cultivated mushrooms from Turkey

This study aimed determining the contents of soluble protein, free amino acid, phenolic, flavonoid, soluble carbohydrate, sugars (glucose, fructose and sucrose) and elements in selected wild growing and cultivated mushroom species collected from various locations of Turkey. Significant differences (P < 0.05) were found for the contents of total free amino acid, soluble protein, phenolic, flavonoid, soluble carbohydrate and sugars. The total free amino acid, soluble protein, phenolic, flavonoid and soluble carbohydrate contents of mushrooms ranged from 33.57–126.57 mg g–1, 2.77–7.55 mg g–1, 28.68–157.39 mg g–1, 8.55– 30.66 mg g–1 and 59.89–343.55 mg g–1, respectively. Elemental analysis showed that mushrooms contained significant amounts of potassium (1345.07–9310.17 mg kg–1), phosphorus (1462.44–6159.45 mg kg–1), calcium (18.78–349.15 mg kg–1), sulphur (952.41–12486.63 mg kg–1), iron (80.62–606.26 mg kg–1), manganese (22.65–147.57 mg kg–1), zinc (103.26–522.81 mg kg–1) and selenium (0–115.40 mg kg–1). Nutritient composition varied with mushroom species. The means of total soluble protein, total phenolic, total flavonoid, potassium, phosphorus, sulphur, chlorine, sodium, iron, calcium, manganese, selenium, zinc and copper contents in wild growing mushrooms were found higher than cultivated mushrooms

The relationship between lipoprotein(a) and coronary artery disease, as well as its variable nature following myocardial infarction

Purpose: The present study aimed to investigate the relationship between the severity of coronary artery disease (CAD) and level of Lipoprotein (LP)(a). Methods: The study included 52 CAD patients and a control group consisting of 38 individuals. The patients were classified into three groups based on the clinical form of CAD (stable angina pectoris, SAP, unstable angina pectoris,UAP, and myocardial infarction,MI), and were further divided into three groups based on CAD severity (1-, 2- and 3-vessel). Serum Lp(a) levels were monitored 4, 8, and 24 h, 10 and 30 days following acute MI in 18 patients. Results: Based on regression analysis, Lp(a) was not correlated with other lipoproteins or with risk factors of CAD, such as body mass index, smoking, family history, diabetes, age, gender, and hypertension (r = 0.08-0.22). 72% of the patients in the CAD group and 24% of the control group had an Lp(a) level > 30 mg dL–1 (P = 0.004), and Lp(a) levels were higher in 3-vessel patients than in 2-vessel and 1-vessel CAD patients (86% vs. 68%, P = 0.02 and 86% vs. 62%, P=0.01, respectively). Serum Lp(a) levels were higher in the UAP and MI groups than in the SAP group (48 ± 44.7 mg dL–1, 49 ± 36.1 mg dL–1 and 31.2 ± 22.3 mg dL–1 , respectively,P=0.02). Lp(a) levels increased after acute MI, and reached peak levels 10 days post-MI (41% increase, P=0.001) and remained considerably elevated (18%) 30 days post-MI (P=0.01). Conclusion: Serum Lp(a) was higher in the UAP and MI patients in comparison with the SAP patients, and was higher in 3-vessel CAD in comparison with 1- and 2-vessel CAD patients